Form 4: Casdin Capital Increases Stake in GeneDx Holdings Corp. (WGS) with Recent Stock Purchases

Casdin Capital, a significant shareholder in GeneDx Holdings Corp., has increased its holdings through recent purchases of Class A Common Stock.

Summary

• Casdin Capital, LLC, along with related entities and individuals, reported changes in beneficial ownership of GeneDx Holdings Corp. (WGS) Class A Common Stock.
• On March 4, 2024, Casdin purchased 40,000 shares at a weighted average price of $8.7427, with individual transactions ranging from $8.6895 to $8.7811.
• On March 5, 2024, an additional 900 shares were purchased at a weighted average price of $8.827, with individual transactions ranging from $8.8236 to $8.84.
• Following these transactions, Casdin Partners Master Fund, L.P. directly owns 2,703,509 shares.
• Eli Casdin directly owns 3,142 shares.
• Casdin Partners FO1-MSV, LP directly owns 432,902 shares.
• CMLS Holdings LLC directly owns 333,144 shares.
• Casdin Capital, LLC, Casdin Partners GP, LLC, and Eli Casdin may be deemed to indirectly beneficially own these shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard trading activity by a major shareholder. The increased investment could be seen as a positive signal, but it's not definitively indicative of strong positive sentiment.

Positives

• Increased investment by a major shareholder could signal confidence in the company's future prospects.

Industry Context

This filing reflects ongoing investment activity by a major shareholder in a publicly traded company within the healthcare sector. Such filings are common and provide transparency into the ownership structure and investment decisions of significant stakeholders.

Stakeholder Impact

• The increased stake by Casdin Capital could be viewed positively by shareholders, potentially increasing investor confidence.

Key Dates